QI
ACAD icon

QS Investors’s Acadia Pharmaceuticals ACAD Stock Holding History

QS Investors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-68,990
Closed -$1.78M – 1095
2021
Q1 		$1.78M Buy
68,990
+55,290
+404% +$2.43M 0.02% 375
2020
Q4 		$732K Hold
13,700
– – 0.01% 608
2020
Q3 		$566K Sell
13,700
-48,700
-78% -$2.1M 0.01% 633
2020
Q2 		$3.02M Sell
62,400
-50
-0.1% -$2.4K 0.04% 343
2020
Q1 		$2.64M Buy
62,450
+100
+0.2% +$4.12K 0.04% 329
2019
Q4 		$2.56M Sell
62,350
-1,500
-2% -$65.3K 0.03% 509
2019
Q3 		$2.3M Hold
63,850
– – 0.03% 523
2019
Q2 		$1.71M Sell
63,850
-139,232
-69% -$3.56M 0.02% 639
2019
Q1 		$5.45M Sell
203,082
-1,553
-0.8% -$36.3K 0.06% 236
2018
Q4 		$3.31M Hold
204,635
– – 0.04% 345
2018
Q3 		$4.25M Buy
204,635
+198,635
+3,311% +$3.13M 0.04% 331
2018
Q2 		$92K Buy
6,000
+4,183
+230% +$74.6K ﹤0.01% 1426
2018
Q1 		$41K Hold
1,817
– – ﹤0.01% 1501
2017
Q4 		$55K Hold
1,817
– – ﹤0.01% 1467
2017
Q3 		$68K Hold
1,817
– – ﹤0.01% 1457
2017
Q2 		$51K Hold
1,817
– – ﹤0.01% 1520
2017
Q1 		$62K Buy
+1,817
New +$64.1K ﹤0.01% 1460
2016
Q4 		– Sell
-9
Closed -$1K – 1920
2016
Q3 		$1K Hold
9
– – ﹤0.01% 1505
2016
Q2 		$1K Sell
9
-16
-64% -$535 ﹤0.01% 1525
2016
Q1 		$1K Buy
25
+16
+178% +$349 ﹤0.01% 1524
2015
Q4 		$1K Buy
+9
New +$317 ﹤0.01% 1531

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

QS Investors's ACAD Position: Q2 2021 in Review

QS Investors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2021, closing a stake of 68,990 shares — an estimated $1.78M sold.

QS Investors first reported a position in ACAD in Q4 2015 and held it in 21 quarters. The position peaked at $5.45M in Q1 2019. 245 funds tracked by Wall St. Rank hold ACAD as of Q2 2021.

  • QS Investors reported no remaining Acadia Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • QS Investors sold 68,990 Acadia Pharmaceuticals shares in Q2 2021, an estimated $1.78M.
  • QS Investors first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • QS Investors's Acadia Pharmaceuticals position peaked at $5.45M in Q1 2019.
  • 245 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.